An investigation on behalf of current long term investors in TherapeuticsMD Inc (NYSEMKT:TXMD) shares over possible breaches of fiduciary duty by certain officers and directors was announced and NYSEMKT:TXMD stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 06/13/2017 -- An investigation on behalf of investors in shares of TherapeuticsMD Inc (NYSEMKT:TXMD) concerning potential breaches of fiduciary duties by certain directors and officers of TherapeuticsMD Inc was announced.
Investors who are current long term investors in TherapeuticsMD Inc (NYSEMKT:TXMD) shares, have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm for current long term investors in NYSEMKT:TXMD stocks follows a lawsuit filed recently against TherapeuticsMD over alleged securities laws violations. The investigation on behalf of current long term investors in NYSEMKT:TXMD stocks, concerns whether certain TherapeuticsMD directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Southern District of Florida the plaintiff alleges that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between July 7, 2016 and April 9, 2017, TherapeuticsMD made false and/or misleading statements and/or failed to disclose that: the Company's New Drug Application (NDA) submission for TX-004HR was deficient, that the NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient, and that the deficient NDA would likely cause a delay of the FDA's potential approval of the TX-0004HR NDA.
Those who purchased shares of TherapeuticsMD Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego